These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 15190680)

  • 21. Biological and genetic markers of sporadic Alzheimer's disease.
    Engelborghs S; De Deyn PP
    Acta Med Okayama; 2001 Apr; 55(2):55-63. PubMed ID: 11332200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in Plasma Amyloid and Tau in a Longitudinal Study of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Chen TB; Lai YH; Ke TL; Chen JP; Lee YJ; Lin SY; Lin PC; Wang PN; Cheng IH
    Dement Geriatr Cogn Disord; 2019; 48(3-4):180-195. PubMed ID: 31991443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neurons derived from sporadic Alzheimer's disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation.
    Ochalek A; Mihalik B; Avci HX; Chandrasekaran A; Téglási A; Bock I; Giudice ML; Táncos Z; Molnár K; László L; Nielsen JE; Holst B; Freude K; Hyttel P; Kobolák J; Dinnyés A
    Alzheimers Res Ther; 2017 Dec; 9(1):90. PubMed ID: 29191219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A data-driven model of biomarker changes in sporadic Alzheimer's disease.
    Young AL; Oxtoby NP; Daga P; Cash DM; Fox NC; Ourselin S; Schott JM; Alexander DC;
    Brain; 2014 Sep; 137(Pt 9):2564-77. PubMed ID: 25012224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Topographical Overlapping of the Amyloid-β and Tau Pathologies in the Default Mode Network Predicts Alzheimer's Disease with Higher Specificity.
    Hojjati SH; Feiz F; Ozoria S; Razlighi QR;
    J Alzheimers Dis; 2021; 83(1):407-421. PubMed ID: 34219729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NEURONORMA Cognitive Battery Associations with Cerebrospinal Fluid Amyloid-β and Tau Levels in the Continuum of Alzheimer's Disease.
    García-Escobar G; Puig-Pijoan A; Puente-Periz V; Fernández-Lebrero A; María Manero R; Navalpotro-Gómez I; Suárez-Calvet M; Grau-Rivera O; Contador-Muñana J; Cascales-Lahoz D; Duran-Jordà X; Boltes N; Pont-Sunyer MC; Ortiz-Gil J; Carrillo-Molina S; López-Villegas MD; Abellán-Vidal MT; Martínez-Casamitjana MI; Hernández-Sánchez JJ; Padrós-Fluvià A; Peña-Casanova J; Sánchez-Benavides G
    J Alzheimers Dis; 2023; 92(4):1303-1321. PubMed ID: 37038810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of the use of biomarkers in cerebrospinal fluid for Alzheimer's disease.
    Valcárcel-Nazco C; Perestelo-Pérez L; Molinuevo JL; Mar J; Castilla I; Serrano-Aguilar P
    J Alzheimers Dis; 2014; 42(3):777-88. PubMed ID: 24916543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein.
    Hampel H; Goernitz A; Buerger K
    Brain Res Bull; 2003 Aug; 61(3):243-53. PubMed ID: 12909294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TNF receptors are associated with tau pathology and conversion to Alzheimer's dementia in subjects with mild cognitive impairment.
    Zhao A; Li Y; Deng Y;
    Neurosci Lett; 2020 Nov; 738():135392. PubMed ID: 32947003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.
    Fagan AM; Shaw LM; Xiong C; Vanderstichele H; Mintun MA; Trojanowski JQ; Coart E; Morris JC; Holtzman DM
    Arch Neurol; 2011 Sep; 68(9):1137-44. PubMed ID: 21555603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
    Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
    Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias.
    Cicognola C; Hansson O; Scheltens P; Kvartsberg H; Zetterberg H; Teunissen CE; Blennow K
    Alzheimers Res Ther; 2021 Feb; 13(1):38. PubMed ID: 33557920
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimer's disease: a longitudinal PET study.
    Ismail R; Parbo P; Madsen LS; Hansen AK; Hansen KV; Schaldemose JL; Kjeldsen PL; Stokholm MG; Gottrup H; Eskildsen SF; Brooks DJ
    J Neuroinflammation; 2020 May; 17(1):151. PubMed ID: 32375809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and
    Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S
    Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic.
    Paterson RW; Slattery CF; Poole T; Nicholas JM; Magdalinou NK; Toombs J; Chapman MD; Lunn MP; Heslegrave AJ; Foiani MS; Weston PSJ; Keshavan A; Rohrer JD; Rossor MN; Warren JD; Mummery CJ; Blennow K; Fox NC; Zetterberg H; Schott JM
    Alzheimers Res Ther; 2018 Mar; 10(1):32. PubMed ID: 29558979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Understanding the cause of sporadic Alzheimer's disease.
    Zetterberg H; Mattsson N
    Expert Rev Neurother; 2014 Jun; 14(6):621-30. PubMed ID: 24852227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cholesterol metabolites and plant sterols in cerebrospinal fluid are associated with Alzheimer's cerebral pathology and clinical disease progression.
    Jahn T; Clark C; Kerksiek A; Lewczuk P; Lütjohann D; Popp J
    J Steroid Biochem Mol Biol; 2021 Jan; 205():105785. PubMed ID: 33171206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.